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M A J O R A R T I C L E
Cumulative HIV Viremia during Highly Active
Antiretroviral Therapy Is a Strong Predictor
of AIDS-Related Lymphoma
Alexander Zoufaly,1 Hans-Jürgen Stellbrink,2 Matthias an der Heiden,3 Christian Kollan,3 Christian Hoffmann,2
Jan van Lunzen,1 Osamah Hamouda,3 and the ClinSurv Study Group
1Infectious Diseases Unit, Department of Medicine, University Medical Center Hamburg-Eppendorf and 2IPM Study Center, Hamburg,
and 3Robert Koch Institute, Berlin, Germany
(See the editorial commentary by Sabin, on pages 8–10.)
Background. AIDS-related lymphoma contributes to significant morbidity and mortality among human im-
munodeficiency virus (HIV)–infected patients receiving highly active antiretroviral therapy (HAART). We assessed
the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-
Hodgkin lymphoma.
Methods. Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational,
open cohort study of HIV-infected patients from different urban areas in Germany, were analyzed using a Cox
proportional hazards model.
Results. In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients
were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated
with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27–2.20]) ( ). ThisP ! .001
association differed markedly between lymphoma subtypes. Although the association was more pronounced for
Burkitt-type lymphoma (HR, 3.45 [95% CI, 1.52–7.85]) ( ), there was no association between cumulativeP p .003
HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39–2.57])
( ). Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4P p .997
T cell count as well as age per 10-year increment.
Conclusions. Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma
among patients receiving HAART. The influence of cumulative HIV viremia may differ between lymphoma subtypes.
The incidence of opportunistic diseases has significantly
decreased among patients infected with human im-
munodeficiency virus (HIV) since the advent of highly
active antiretroviral therapy (HAART); however, the de-
crease in the incidence of AIDS-related lymphomas has
been less marked [1–3]. Malignant lymphomas have
become the most common AIDS-related cancers and
are associated with poor overall survival. They con-
tribute to significant morbidity and mortality, including
up to 30% of AIDS-related deaths [4–7]. Depending
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on the lymphoma subtype, the risk of developing lym-
phoma is up to 165 times higher for HIV-infected in-
dividuals than for non–HIV-infected individuals, and
HAART does not eliminate the risk of lymphoma, de-
spite observations of an ∼10-fold reduction in incidence
rates when HAART is given over a long period [8–11].
AIDS-related lymphomas represent a heterogeneous
entity of diseases, and distinct risk factors may prevail.
The influence of immunity on the risk of lymphoma
seems to be variable for lymphoma subtypes. In one
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large HIV/AIDS Cancer Match Study, Burkitt-type lymphoma
was not associated with the CD4 cell count, whereas primary
central nervous system (CNS) lymphoma clearly was [12].
Other studies have suggested that HIV replication may influ-
ence lymphomagenesis due to consecutive immune activation
and B cell stimulation [13, 14]. Viral suppression below the
limit of detection of current assays has been shown to be pro-
tective, but little is known about the risk of lymphoma among
individuals who have viremic episodes while receiving HAART
[15]. Intermittent viremia is not uncommon among individuals
receiving HAART, and, in one cohort study [16], it was de-
tectable during almost 18% of follow-up while individuals were
receiving HAART. In the present study, we analyzed risk factors
for the development of AIDS-related lymphoma and lymphoma
subtypes in a large cohort of HIV-infected patients receiving
HAART, with a particular focus on HIV plasma viremia.
PATIENTS AND METHODS
Cohort. The Clinical Surveillance of HIV Disease (ClinSurv)
study is an ongoing, prospective, observational cohort study
currently comprising 18,451 HIV-infected patients monitored
at 18 clinical centers in different urban areas in Germany. All
HIV-infected patients who were consecutively observed begin-
ning on 1 January 1999 were enrolled in the study. Patients are
routinely seen in a clinic every 3 months, according to national
guidelines. Biannual data collection is performed using local
computerized databases, with information on all CD4 T cell
counts and viral load measurements gathered, as well as data
on all clinical events, antiretroviral therapy (ART) initiation,
or changes occurring since the time of the first visit at the
reporting center. All time-related variables are collected and
referenced according to the day of occurrence. Data are vali-
dated and monitored manually as well as electronically at the
coordinating center (Robert Koch Institute); source data are
verified; and double reporting is excluded. The ClinSurv study
has been approved by the Federal Commissioner for Data Pro-
tection and Freedom of Information.
Data analysis. This analysis included all patients receiving
HAART for whom no diagnosis of lymphoma was made either
before or 30 days after HAART initiation, because patients who
were given a diagnosis during this period were considered to
have prevalent lymphomas. HAART was defined as combina-
tion therapy involving at least 3 antiretroviral drugs (either
therapy containing a protease inhibitor or nonnucleoside re-
verse-transcriptase inhibitor or therapy containing 3 nucleoside
reverse-transcriptase inhibitors).
For the survival analysis, the length of follow-up was cal-
culated as (1) the time from initiation of HAART (i.e., baseline)
to either diagnosis of AIDS-related lymphoma, last follow-up,
or 3 December 2006; or (2) a maximum of 3500 days of follow-
up (e.g., completion of 10 years), after which time too few
patients were left in the cohort. Patients were included in the
analysis only if at least one measurement of the CD4 T cell
count and 2 measurements of the plasma viral load were avail-
able within this period. Because of the different methods of
viral load measurement used and because of previous use of
earlier versions of HIV RNA assays that had higher thresholds
of detectability, a cutoff level of 500 HIV RNA copies/mL was
defined as the limit of detection.
Definition of AIDS-related lymphoma. Incident AIDS-re-
lated lymphoma was defined as lymphoma occurring at a min-
imum of 30 days after initiation of HAART. This period was
chosen based on the rapid tumor growth that characterizes
these tumors clinically. A sensitivity analysis including only
those lymphomas that developed 90 days after of initiation of
HAART yielded similar results. Lymphoma classification was
performed by local pathologists on the basis of biopsy or au-
topsy findings, and every participating center vouched for the
correct classification [10]. Because central reviewing of speci-
mens was not possible, we restricted lymphoma classification
to 4 groups: Burkitt-type lymphoma (Burkitt and Burkitt-like
lymphoma), non-Burkitt high-grade B cell lymphoma (includ-
ing diffuse large B cell lymphoma and primary effusion lym-
phoma), documented lymphoma for which no histologic di-
agnosis was available, and primary CNS lymphoma. Low-grade
lymphomas were excluded.
As an internal control, the influence of viremia and other
risk factors was also analyzed for cases of incident Candida
esophagitis in the absence of AIDS-related lymphoma, because
we assumed no influence of viremia independent of CD4 cell
counts for this event. All patients without a diagnosis of lym-
phoma were included in this analysis. A univariate and mul-
tivariable Cox model that incorporated the same variables that
were used in the analysis of lymphomas was fitted. Similar to
what was done in the analysis of lymphomas, the length of
follow-up was calculated as the time from initiation of HAART
to either the time that Candida esophagitis was newly diagnosed
(based on clinical reports), last follow-up, or 31 December
2006. Variables that were significantly associated with an in-
creased risk of Candida esophagitis in the univariate analysis
were included in the multivariable model.
Analysis of viremia. To analyze the influence of HIV viremia,
we first categorized patients with and without a lymphoma di-
agnosis according to whether viral load measurements 1500 cop-
ies/mL were noted in !25%, 25%–50%, 51%–75%, or 175% of
all available viral load test results. All patients who had at least
one CD4 T cell count and one viral load measurement obtained
during follow-up were included in the analysis. We noticed a
significantly increased risk of lymphoma development in the
highest (175%) category in a Cox proportional hazards model
(including 79 patients with lymphoma and 6348 patients with-
out a lymphoma diagnosis) (figure 1, which appears only in the
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Figure 1. Influence of persistent viremia
electronic version of the Journal). To account for the possibility
that successive measurements made during a short period might
have biased the results for persistent viremia as described above,
we analyzed the area under the curve of the log viral load to
quantify cumulative viremia more accurately.
Variable selection and statistical modeling. Factors asso-
ciated with the diagnosis of AIDS-related lymphoma were as-
sessed in Cox models. Proportional hazards assumptions were
confirmed by Schoenfeld’s tests. The variables tested included
possible confounders or effect modifiers, such as age at baseline,
sex, HIV transmission group, origin, AIDS-defining illness be-
fore initiation of HAART, previous exposure to antiretroviral
monotherapy or dual therapy, and calendar period when
HAART was initiated (before 1 January 2001 vs. after 1 January
2001, when modern protease inhibitor therapy became widely
available in Germany). To account for the fact that patients
could have interrupted therapy during follow-up, the total per-
centages of follow-up time spent receiving or not receiving
HAART were calculated for each individual patient and were
introduced into the model as a fixed covariate (table 1). Im-
munologic variables included the nadir CD4 T cell count before
initiation of HAART, the CD4 T cell count at baseline, and the
time-updated latest CD4 T cell count.
To assess the influence of HIV viremia and to find the best
possible predictor for lymphoma, we tested the HIV load at
baseline, the maximum HIV load, and the time-updated latest
HIV load. The latest CD4 cell count and viral load were grouped
into clinically meaningful categories (table 2).
In addition, cumulative viremia was modeled as the time-
updated area under the curve of the log viral load. Every viral
load measured had an attributed period of validity extending
to the previous measurement or a maximum of 180 days. A
viral load below the limit of detection (500 HIV RNA copies/
mL) did not contribute to the calculation of cumulative vire-
mia. The area under the curve was calculated by totaling the
product of the log viral load and its corresponding period of
validity (figure 2). Using cumulative viremia in the Cox model,
we observed risk saturation at ∼7000 days  log HIV RNA
copies/mL. To explain and further investigate this risk satu-
ration, we constructed a cumulative viremia variable with a
finite memory that included only those viral load values that
had accumulated in the 3 years before the current follow-up
in an alternative model.
Baseline characteristics of patients with lymphoma and of
patients with different lymphoma subtypes diagnosed during
follow-up were compared with the characteristics of patients
without lymphoma, by use of the test and the nonparametric2x
rank-sum test. All variables were tested in a univariate analysis
and were then included in a multivariable model with stepwise
reduction of variables for which . All analyses were per-P 1 .1
formed using Stata software (version 10; Stata). wasP ! .05
considered to denote statistical significance, and all tests of
significance were 2-sided.
RESULTS
From 1 January 1999 through 31 December 2006, a total of
6704 HIV-infected patients in the ClinSurv cohort study re-
ceived HAART. Of a total of 284 cases of AIDS-related lym-
phoma, 185 were considered to be prevalent at the time of
initiation of HAART and were excluded from the study. The
remaining 99 cases were diagnosed at least 30 days after ini-
tiation of HAART and were considered to be incident cases. A
total of 6022 patients, including 66 patients with incident lym-
phoma, had at least 1 documented CD4 T cell count and 2
viral load measurements during follow-up and were included
in the analysis of cumulative viremia (table 2).
Based on a total of 27,812 person-years in this analysis, the
incidence of any lymphoma developing was 2.4 cases/1000 pa-
tient-years (95% confidence interval [CI], 1.8–3.0 cases/1000
patient-years). Characteristics at baseline, according to lym-
phoma subtypes, are listed in table 1. In an additional analysis
138 HIV-infected patients with incident Candida esophagitis
(i.e., cases occurring 130 days after initiation of HAART) and
without a diagnosis of lymphoma were identified and analyzed.
Demographic data and HAART. Characteristics at baseline
were heterogeneous for patients with lymphoma and those
without lymphoma (table 1). There was no difference with
respect to the total percentage of follow-up time when HAART
was received. The mean observation time was 754 days (inter-
quartile range [IQR], 327–1847 days) in the lymphoma group,
compared with 1520 days (IQR, 730.5–2645 days) in the non-
lymphoma group ( ). The frequency of viral load testingP ! .01
per year was similar among patients with lymphoma and lym-
phoma subtypes, with the exception of patients with Burkitt-
type lymphoma, for whom the frequency of testing was higher
(5.57 vs. 3.97 measurements/year; ) (table 1).P p .005
Immunologic and virologic data. The CD4 T cell count
nadir before initiation of HAART was significantly lower in the
lymphoma group. The CD4 T cell count at baseline was 90
cells/mL (IQR, 38–220 cells/mL) in the lymphoma group versus
204 cells/mL (IQR, 80–340 cells/mL) in the nonlymphoma group
( ). The log viral load at initiation of HAART (i.e., atP ! .01
baseline) was higher among patients with lymphoma than
among patients without lymphoma (5.14 vs. 4.81 HIV RNA
copies/mL; ).P p .01
Lymphoma characteristics. Of the 66 patients with lym-
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Table 2. Cox proportional hazards model for all incident AIDS-related lymphomas ( ) and cases of incidentn p 66











HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age at baselinea 1.43 (1.16–1.76) !.001 1.42 (1.15–1.75) .001 … …
Sex, male 2.78 (1.12–7.14) .03 … … … …
Transmission risk among MSMb 1.44 (0.87–2.39) .16 … … … …
Germany as originc 1.37 (0.72–2.62) .34 … … … …
AIDS-defining illness before HAART initiation 2.78 (1.71–4.51) !.001 … … … …
ART naive at HAART initiationd 0.94 (0.57–1.55) .81 … … … …
HAART initiation on or after 1 Jan 2001e 0.91 (0.51–1.62) .75 … … … …
Follow-up time receiving HAART,f % 1.06 (0.95–1.19) .23 … … 0.86 (0.81–0.91) !.001
CD4 T cell count, cells/mL
Nadir of !200 before HAART initiationg 5.91 (2.51–13.91) !.001 … … … …
Latest … … … …
!200h 19.19 (6.76–54.48) !.001 8.16 (3.90–17.10) !.001 7.64 (4.74–12.29) !.001
201–350h 10.35 (3.57–30.06) !.001 5.21 (2.46–11.03) !.001 2.38 (1.39–4.05) .01
351–500h 2.60 (0.73–9.21) .14 … … … …
Latest viral load, copies/mL
500–10,000i 0.84 (0.30–2.34) .73 … … 2.05 (1.15–3.65) .01
10,001–100,000i 3.14 (1.67–5.90) !.001 … … 1.96 (1.11–3.48) .02
1100,000i 5.60 (2.86–10.97) !.001 … … 6.27 (3.69–10.64) !.001
Cumulative HIV viremiaj 2.17 (1.66–2.85) !.001 1.67 (1.27–2.20) !.001 1.11 (0.91–1.36) .30
NOTE. ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; MSM, men who have sex with men.
a Per 10-year increment.
b Compared with other transmission groups.
c Compared with other countries of origin.
d Compared with prior exposure to antiretroviral monotherapy or dual therapy and unknown pretreatment status.
e Compared with HAART initiation before 1 January 2001.
f Per 10%.
g Compared with a CD4 T cell count nadir of 200 CD4 T cells/mL.
h Reference group, 1500 CD4 T cells/mL.
i Reference group, 500 copies/mL.
j Per 2000 days  log HIV RNA copies/mL (reference group, 0 days  log HIV RNA copies/mL). For the alternative model of cumulative
viremia in the past 3 years, the HR was 1.81 (95% CI, 1.32–2.49) ( ) in the multivariable analysis.P ! .001
had Burkitt-type lymphoma, 32 (48.5%) had non-Burkitt high-
grade B cell lymphoma, 8 (12.1%) had primary CNS lym-
phoma, and 15 (22.7%) had AIDS-related lymphoma, not
otherwise specified. Four of the patients with AIDS-related
lymphoma (6% of the 66 patients with lymphoma included in
the study) had clinically suspected lymphoma. When these 4
patients with clinically suspected lymphoma were excluded, a
sensitivity analysis yielded similar results (data not shown).
Compared with the 66 patients with lymphoma who were in-
cluded in the analysis, the 33 patients with lymphoma who
were excluded from the study because they lacked CD4 cell
counts or viral load data were significantly younger (mean age,
39.2 vs. 43.7 years; ), less often received a diagnosis ofP p .03
AIDS before initiation of HAART (mean frequency, 27.3% vs.
53.0%; ), and had a shorter time to lymphoma diag-P p .02
nosis (mean, 261 vs. 754 days; ). There was no differ-P ! .001
ence in terms of transmission risk, sex, country of origin, year
of initiation of HAART, ART-naive status, or percentage of
follow-up time during which HAART was received.
Risk factors in the univariate and multivariable analyses.
In a univariate analysis, baseline risk factors that were associated
with an increased risk for the development of any lymphoma
were age per 10-year increment, male sex, AIDS-defining illness
before initiation of HAART, and a CD4 T cell count nadir of
!200 cells/mL. CD4 T cell counts in the lowest 2 categories
(!200 cells/mL and 201–350 cells/mL) and a latest plasma viral
load of 10,001–100,000 HIV RNA copies/mL were also as-
sociated with the risk of lymphoma. The hazard ratio (HR) for
the incidence of lymphoma increased per 2000 days  log HIV
RNA copies/mL (table 2).
In a multivariable analysis, age per 10-year increment (HR,
1.42 [95% CI, 1.15–1.75]; ) and CD4 T cell counts ofP p .001
!200 cells/mL (HR, 8.16 [95% CI, 3.90–17.10]; ) andP ! .001
201–350 cells/mL (HR, 5.21 [95% CI, 2.46–11.03]; )P ! .001
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Figure 2. Construction of cumulative viremia, with calculation of the time-updated area under the curve of the log-viral load. The log viral load (*)
was multiplied by the corresponding period of validity (R) extending to the previous viral load measurement (*) or a maximum of 180 days. The gray-
shaded area under the curve denotes cumulative viremia. The area below the detection limit (!500 human immunodeficiency virus RNA copies/mL)
was not calculated.
Figure 3. Cox proportional hazards model illustrating the influence of
cumulative human immunodeficiency virus viremia on lymphoma-free sur-
vival. Stratum: CD4 T cell count !200 cells/mL.
remained independently associated with the risk of develop-
ment of any lymphoma. In addition, cumulative viremia was
highly associated with the risk of lymphoma (HR per 2000 days
 log HIV RNA copies/mL, 1.67 [95% CI, 1.27–2.20]; P !
). The influence of cumulative viremia, as stratified by a.001
CD4 T cell count of !200 cells/mL, is depicted in figure 3.
Analysis of lymphoma subtypes and Candida esophagitis.
Additional univariate and multivariable analyses were per-
formed to analyze the risk factors for lymphoma subtypes and
Candida esophagitis. Time receiving HAART, the latest CD4 T
cell count assigned to the 2 lowest categories (!200 cells/mL
and 201–350 cells/mL), and cumulative HIV viremia were all
significantly associated with the risk for non-Burkitt high-grade
lymphoma. In contrast, cumulative HIV viremia was the only
risk factor highly associated with a diagnosis of Burkitt-type
lymphoma. The HR for cumulative HIV viremia was higher
for Burkitt-type lymphoma (HR per 2000 days  log HIV RNA
copies/mL, 3.45 [95% CI, 1.52–7.85]; ) than for non-P p .003
Burkitt high-grade lymphoma (HR per 2000 days  log HIV
RNA copies/mL, 2.02 [95% CI 1.37–2.98]; ).P ! .001
There was no association between cumulative HIV viremia
and diagnosis of primary CNS lymphoma. Age per 10-year
increment (HR, 1.83 [95% CI, 1.03–3.24]; ) and aP p .040
CD4 cell count !200 cells/mL (HR, 6.53 [95% CI, 1.44–29.51];
) were the only risk factors significantly associated withP p .015
a diagnosis of CNS lymphoma (table 3).
In a multivariable analysis, there was no association between
cumulative HIV viremia and diagnosis of Candida esophagitis.
Duration of HAART and a CD4 T cell count of !200 cells/mL
or 201–350 cells/mL, as well as the latest viral load in 3 catego-
ries above the threshold of detection (500–10,000 copies/mL,
10,001–100,000 copies/mL, and 1100,000 copies/mL) were all
associated with the risk of Candida esophagitis (table 2).
A similar influence of cumulative HIV viremia was observed
for all lymphomas (HR per 2000 days  log HIV RNA copies/
mL, 1.81 [95% CI, 1.32–2.49]; ) and for Burkitt-typeP ! .001
lymphomas (HR per 2000 days  log HIV RNA copies/mL,
3.46 [95% CI, 1.51–7.92]; ), when analyzing cumu-P p .003
lative HIV viremia only in the 3 years preceding the time of
the most recent follow-up, the date of lymphoma diagnosis, or
the censoring date, respectively.
DISCUSSION
The present study provides evidence supporting the strong
influence of HIV replication on lymphomagenesis. The HR
for the development of lymphoma increased with the accu-
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HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age at baselinea … … … … 1.83 (1.03–3.24) .04
Follow-up time receiving HAART,b % … … 1.48 (1.10–1.98) .01 … …
Latest CD4 T cell count,c cells/mL
!200 … … 9.95 (3.14–31.51) !.001 6.53 (1.44–29.51) .02
201–350 … … 7.78 (2.50–24.19) !.001 … …
Cumulative HIV viremiad 3.45 (1.52–7.85) .003 2.02 (1.37–2.98) !.001 1.00 (0.39–2.57) 1.00
NOTE. CI, confidence interval; CNS, central nervous system; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency
virus; HR, hazard ratio; NHL, non-Hodgkin lymphoma.
a Per 10-year increment.
b Per 10%.
c Reference group, CD4 T cell count 1500 cells/mL.
d Per 2000 days  log HIV RNA copies/mL (reference group, 0 days  log HIV RNA copies/mL).
mulation of HIV viremia during follow-up, independent of
the latest CD4 T cell count.
Previous cohort study analyses suggested that the risk of
lymphoma was lower among patients who had a viral load of
!500 HIV RNA copies/mL and that plasma viremia might be
an independent risk factor, but these possibilities were not fur-
ther investigated in a multivariable analysis [15, 17]. In another
study, an HIV load above the limit of detection was associated
with the development of new opportunistic diseases in patients
receiving HAART [18]. However, in our study, cumulative HIV
viremia (rather than the latest viral load) best predicted the
development of lymphoma, suggesting an important effect of
sustained viremia over time and a distinct pathogenesis of
AIDS-related lymphoma, compared with other opportunistic
diseases.
The present study had several limitations, which were mainly
the result of the study design. First, we included only patients
who were receiving HAART. We were unable to analyze how
much viremia had accumulated before the initiation of HAART.
Of note, however, the effect of cumulative viremia remained
highly significant when only viremia accumulated in the 3 years
before current follow-up was included. This finding indicates
that recent viremia might be most relevant for lymphomagene-
sis and that the risk of lymphoma is reduced when full viral
suppression is sustained over a minimum of 3 years.
Second, although the CD4 cell count and the viral load are
routinely checked every 3 months, in accordance with local
guidelines, there may have been inconsistencies in the frequency
and number of data collection time points, as well as in the types
of assays used for analysis in the participating centers. We con-
structed the cumulative viremia, assuming the comparability of
licensed and validated viral load tests, to account for missing
viral load measurements during an individual’s follow-up. This
was done in an attempt to include the largest number of patients
possible and not to restrict this analysis to patients who had a
complete follow-up. However, exclusion of patients with lym-
phoma who were lacking CD4 cell count or viral load data could
have led to an overestimation of the influence of age and a
previous AIDS diagnosis on lymphomagenesis.
Third, although end points were carefully verified by re-
viewing clinical reports and results of histologic examination,
central reviewing of lymphoma histopathologic findings and
further classification of lymphomas with unknown histology
were not possible in this clinical cohort analysis. Given the
difficulties in the diagnosis and correct classification of AIDS-
related lymphoma, we cannot entirely exclude the possibility
that some cases had not been classified correctly. Burkitt-type
lymphoma, however, is an entity that is more clearly defined
and has more distinct clinical and histopathologic findings than
do other types of high-grade non-Hodgkin lymphoma (NHL)
[19]. Furthermore, high-grade malignant primary cerebral
NHL is characterized by its almost exclusive localization within
the CNS. Therefore, despite the possibility of some misclassi-
fication, we regarded it as justified to group the tumors for the
analysis as outlined above.
Finally, in the subtype analysis, only a small number of cases
of Burkitt lymphoma and primary CNS lymphoma were avail-
able, resulting in wider confidence intervals and a less reliable
multivariable model. This warrants further investigation in even
bigger cohorts.
Despite these limitations, which are typical of cohort studies,
we regard these results as important. To our knowledge, this
is the first study to show that uncontrolled HIV replication
during HAART, as assessed by cumulative HIV viremia, is pre-
dictive of the development of AIDS-related lymphoma. This
effect seems to be strongest for high-grade NHL other than
primary cerebral lymphoma. By contrast, no independent in-
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fluence of cumulative viremia on incident primary CNS lym-
phoma or Candida esophagitis was observed.
The underlying mechanisms, however, remain unclear. Per-
sistently elevated serum globulin levels, an indicator of chronic
B cell stimulation, are associated with an increased risk of lym-
phoma, probably because of an increased turnover of B cells
and accumulating genetic aberrations, giving rise to malignant
B cell clones [13]. B cell stimulation may persist for a long
period, even when viral replication is profoundly suppressed
by HAART [14]. The clear influence of cumulative viremia on
the risk of Burkitt-type NHL in our study suggests that this
tumor entity might be especially promoted by factors associated
with viral replication, such as B cell activation and accumu-
lation of viral proteins in germinal centers, the anatomical site
of B cell maturation and differentiation. In non–HIV-infected
patients, Epstein-Barr virus may drive development of classical
Burkitt lymphoma; however, this virus has been shown to be
associated with only 50% of HIV-associated Burkitt-type lym-
phomas, and its role in lymphomagenesis is not entirely clear
[20, 21]. In fact, ongoing replication of HIV might similarly
trigger development of Burkitt-type lymphomas in HIV-in-
fected patients.
Low CD4 T cell counts were shown to be associated with
several AIDS-defining diseases, including AIDS-associated ma-
lignancies [12, 22–25]. Therefore, reduced immunosurveillance
apparently contributes to an increased risk for the development
of tumors. In this study, the risk of lymphoma was highest
when the latest CD4 cell count was !200 cells/mL (HR, 8.16).
Of note, 10 (15.2%) of 66 lymphomas occurred at a CD4 cell
count of 1350 cells/mL, indicating a significant influence of risk
factors other than the latest CD4 cell count.
In conclusion, providing longitudinal data from a large mul-
ticenter clinic-based cohort, we are able to demonstrate that
uncontrolled HIV replication during HAART, as assessed by
cumulative HIV viremia, is predictive of the development of
lymphoma. The effect seems to be strongest for Burkitt-type
lymphoma, whereas primary CNS lymphoma may be more
similar to an opportunistic infection such as Candida esoph-
agitis. In line with other studies, the latest CD4 cell count and
age were also associated with the risk of lymphoma. Therefore,
cumulative HIV viremia during HAART represents an addi-
tional (yet undescribed) and potentially modifiable risk factor.
These results should encourage physicians to optimize
HAART for patients with persisting HIV replication, in an at-
tempt to achieve complete viral suppression and to minimize
the risk of this life-threatening complication.
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